<DOC>
	<DOCNO>NCT00431574</DOCNO>
	<brief_summary>In patient stabilize antipsychotic demonstrating evidence good clinical response , significant change symptom medication decrease every 2 day rather daily . This decrease antipsychotic exposure lead reduction side effect , well improve subjective response treatment .</brief_summary>
	<brief_title>Antipsychotic Medication Extended Dosing Study</brief_title>
	<detailed_description>The present study 6-month , double-blind study patient schizophrenia stabilize current antipsychotic ( monotherapy ) period least 3 month . After provide informed consent , individual randomly assign 1 2 treatment arm : regular daily antipsychotic dose active medication daily dose every 2nd day . Various scale measure clinical response side effect administer baseline , well every 2 week thereafter . Subjective scale also employ , lab evaluation include plasma antipsychotic level baseline endpoint , well prolactin . Our sample size 20/group .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>DSMIV diagnosis schizophrenia schizoaffective disorder Capacity provide write , informed consent Stabilized* single oral antipsychotic least three month ( exclude CLOZAPINE QUETIAPINE ) Evidence compliance previous antipsychotic treatment , i.e . great 90 % * define 2 consecutively identical CGI evaluation ( screen baseline , least one week apart ) exposure depot antipsychotic 12 month prior enrollment substancerelated disorder accord DSMIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>randomize control trial</keyword>
</DOC>